Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

 

Highlights this week included:

Mucinex (Guaifenesin ) – US: CAFC: Construction of pharmacokinetic claim terms: Adams Respiratory Therapeutics v. Perrigo (Patently-O) (Patent Docs)

 

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

 

General

Who are the leading drug inventors and where do they live? (Biotech Blog)

Gene patents – a lawyer’s trick? (IP Whiteboard)

Australia: A tale of four amendment requests: Bristol-Myers Squibb Company v. Apotex Pty Ltd; CSL Limited v. Novo Nordisk Pharmaceuticals Pty Ltd; Zetco Pty Ltd v. Austworld Commodities Pty Ltd; Apotex Pty Ltd v. Les Laboratoires Servier (No 2) (Patentology)

India: Post grant oppositions – new decisions: Richter v Cipla; Novartis v Cipla (Generic Pharmaceuticals and IP)

Mexico: COFEMER and AMELAF comment on Biotech Regulations in Mexico (Patent Docs)

US: American Bar Association files amicus brief in Therasense case (Patent Docs)

US: Biopolymer Engineering and MIT fail to get vacation (of summary judgment): Biopolymer Engineering and MIT v. Immunocorp and Biotec Pharmacon ASA (Patent Baristas)

US: Claim construction of DNA reciting claims: Intervet Inc. v. Merial Ltd. (Fed. Cir. 2010) (Patent Docs) (Patent Docs)

US: CAFC: Inherent anticipation and inherent obviousness? King Pharmaceuticals, Inc. v. Eon Labs, Inc. (Patent Docs)

US: Kevin Collins: Printed matter doctrine as a structural doctrine and its implications for Prometheus Laboratories: King Pharmaceuticals, Inc. v. Eon Labs, Inc. (Patently-O)

US: New analysis takes issue with CBO patent settlement legislation cost estimate (FDA Law Blog)

Products

Antara (Fenofibrate) – US: Patent infringement complaint filed following a Paragraph IV certification: Lupin Atlantis Holdings SA v. Ranbaxy Laboratories Ltd. et al. (Patent Docs)

Asacol (Mesalamine) – US: Patent infringement complaint filed following a Paragraph IV certification: Medeva Pharma Suisse A.G. et al. v. Par Pharmaceutical, Inc. et al. (Patent Docs)

Fabrazyme (Agalsidase) – US: Genzyme’s manufacturing issues with Fabrazyme prompt patients to petition HHS secretary to exercise Bayh-Dole ‘March-in’ rights (Patent Docs)

Felodipine/ Metoprolol – Sweden: AB Hässle combination product case: informal translation available (SPC blog)

Lipitor (Atorvastatin) – US: Patent infringement complaint filed following a Paragraph IV certification: Pfizer Inc. et al. v. Actavis Group Hf et al (Patent Docs) (GenericsWeb)

Lunesta (Eszopiclone) – US: Glenmark Pharmaceuticals and Sepracor settle Lunesta patent litigation (Patent Docs)

Mirapex (Pramipexole) – US: Sandoz ends attempt to market generic Mirapex (Patent Docs)

Mucinex (Guaifenesin ) – US: CAFC: Construction of pharmacokinetic claim terms: Adams Respiratory Therapeutics v. Perrigo (Patently-O) (Patent Docs)

Naropin (Ropivacaine) – US: Complaint for patent infringement filed: APP Pharmaceuticals, LLC v. Ameridose, LLC (Patent Docs)

Neutrokine-α – UK: Supreme Court to hear patent dispute concerning Neutrokine-α and industrial applicability on 7 October: Eli Lilly & Co v Human Genome Sciences Inc (IPKat)

Nuvigil (Armodafinil) – US: Cephalon and Mylan Pharmaceuticals agree to drop two patents from Nuvigil patent suit (Patent Docs)

OxyContin (Oxycodone) – Patent infringement complaint filed following a Paragraph IV certification: Purdue Pharma L.P. et al. v. Varam, Inc. et al. (Patent Docs)

Prandin (Repaglinide) – US: Drugmakers get broader protection from generics after Court says ‘A’ means ‘Any’:  Novo Nordisk A/S v. Caraco Pharmaceutical Labs and Sun Pharmaceutical Ind. (Patent Baristas)

Strattera (Atomoxetine) – US: District Court rules against Lilly regarding Strattera patent: Eli Lilly v Actavis Elizabeth (GenericsWeb)

Vigamox (Moxifloxacin) – US: Alcon denied permanent injunction against Teva in Vigamox litigation (Patent Docs)